TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04055766

Intervention type: DEVICE
Intervention: DeepDoc AI-based Decision Support System
Description: Patients are diagnosed by the DeepDoc within 24 hours of admission.

Intervention type: DEVICE
Intervention: DeepDoc AI-based Decision Support System
Description: Patients are diagnosed by the DeepDoc within 24 hours of admission.

Intervention type: DEVICE
Intervention: DeepDoc AI-based Decision Support System
Description: Patients are diagnosed by the DeepDoc within 24 hours of admission.

Intervention type: DEVICE
Intervention: DeepDoc AI-based Decision Support System
Description: Patients are diagnosed by the DeepDoc within 24 hours of admission.
Study: NCT04307407

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Participants will be randomized to supervised aerobic exercise or standard care. Women with no current or past malignant disease will comprise the reference group and will be matched for age to participants in the Aerobic Exercise arm

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Aerobic Exercise
Description: Participants will be randomized to supervised aerobic exercise or standard care. Women with no current or past malignant disease will comprise the reference group and will be matched for age to participants in the Aerobic Exercise arm
Study: NCT02168751

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Study: NCT04320186

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Entertainment education

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Entertainment education

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: video
Description: video
Study: NCT04418323

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Video-assisted anal fistula treatment (VAAFT) versus Fistula-tract Laser Closure (filac) versus Conventional seton in the Management of anal fistula
Description: Video-assisted anal fistula treatment (VAAFT) versus Fistula-tract Laser Closure (filac) versus Conventional seton in the Management of anal fistula

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Video-assisted anal fistula treatment (VAAFT) versus Fistula-tract Laser Closure (filac) versus Conventional seton in the Management of anal fistula
Description: Video-assisted anal fistula treatment (VAAFT) versus Fistula-tract Laser Closure (filac) versus Conventional seton in the Management of anal fistula

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Video-assisted anal fistula treatment (VAAFT) versus Fistula-tract Laser Closure (filac) versus Conventional seton in the Management of anal fistula
Description: Video-assisted anal fistula treatment (VAAFT) versus Fistula-tract Laser Closure (filac) versus Conventional seton in the Management of anal fistula
Study: NCT00545077

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Study: NCT01966055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solithromycin
Study: NCT00362726

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone maleate
Description: Tablets, Oral, RGZ 4 mg, once daily, 1 day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir Sulphate
Description: Capsules, Oral, ATV 400 mg, once daily, 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir Sulphate + Rosiglitazone maleate
Description: Capsule, Oral, ATV 400 mg + RGZ 4 mg, once daily, 1 day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir Sulphate + Ritonavir
Description: Capsules, Oral, ATV 300 mg + RTV 100 mg, once daily, 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir Sulphate + Ritonavir + Rosiglitazone maleate
Description: Capsules/Tablets, Oral, ATV 300 mg + RTV 100 mg + RGZ 4 mg, once daily, 1 day.
Study: NCT03684213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control (Norepinephrine)
Description: This intervention is aimed at assessing the vascular responsiveness to norepinephrine, an alpha 1-agonist, in white and black men and women across a series of ascending dose concentrations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine + Ascorbic Acid
Description: This intervention is meant to globally assess the impact of oxidative stress on vasoconstrictor responses by scavenging numerous oxidative molecules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine + L-NAME
Description: This intervention is meant to assess the impact of endothelium-derived nitric oxide on vasoconstrictor responses by inhibiting production of this source of nitric oxide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine + L-NAME + Ascorbic Acid
Description: This intervention is meant to assess the combined impact of scavenging oxidative stress and inhibiting endothelium-derived nitric oxide on vasoconstrictor responses.
Study: NCT02955134

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is simulate granule of Chinese medicine application prescription. Patients take 200ml each time, twice a day. Treatment duration are 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Azimtamide Entieric-coated Tablets
Description: Compound Azimtamide Entieric-coated Tablets are qualified by China Food and Drug Administration. These tablets are allowed to be taken when patients feel fullness, belching or anorexia. Continuous taking time should not exceed one week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Compound Azimtamide Entieric-coated Tablets
Description: Compound Azimtamide Entieric-coated Tablets are qualified by China Food and Drug Administration. These tablets are allowed to be taken when patients feel fullness, belching or anorexia. Continuous taking time should not exceed one week.
Study: NCT01002794

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic partial menisectomy
Description: Standard arthroscopic partial meniscectomy, NGD 1. Carried out at Ullevaal University Hospital and Martina Hansens Hospital.
Study: NCT03816124

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Description: radiofrequency ablation of the genicular nerves
Study: NCT04195516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: web based training,individual counseling, using reminders
Description: Health Promotion Model based Health Promotion Program will be applied to the experimental group. Health promotion program; The Web-based Health Promotion Program includes individual counseling and reminder practices.~Within the context of the Web Based Health Promotion Program, 8 weeks of training to improve healthy eating and physical activity behaviors, individual counseling will be given.~Colorful picture reminders will be sent to the experimental group through Whatsapp groups.~At the end of the intervention, cognitive and physical measurements of the students will be done at 1st, 3rd and 6th months.
Study: NCT02056535

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Motivational Intervention
Description: A short discussion is held with patients identifying pros and cons of their drinking, readiness for change is assessed, and a brief prescription drawn for behavior change signed by the patient.
Study: NCT03506880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MADD Materials
Description: Handbook developed by MADD and the PI to guide parents in discussing underage drinking, behaviors, and consequences with their teens
Study: NCT01869114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study: NCT03506880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surgeon General Materials
Description: Information published by the Surgeon General about teens and drinking
Study: NCT01669382

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous coronary intervention
Description: after the intervention patients are randomized to either Angio Seal or Exo Seal

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous coronary intervention
Description: after the intervention patients are randomized to either Angio Seal or Exo Seal
Study: NCT01869114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV
Study: NCT02010372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reminder Recall Report
Description: Practices (administrators) that are randomized to this intervention will receive training in how to run reminder recall reports for patients due to receive any dose of HPV vaccine. After the training has been completed, administrators will be asked to continue running regularly scheduled reports over the course of one year. A tracking log will be sent regularly to the research team.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audit-Feedback/Immunization Forecasting Reports
Description: Practices (administrators) that are randomized to this intervention will receive training in how to run audit-feedback/immunization forecasting reports for patients due to receive any dose of HPV vaccine and to determine the % of patients in their practice who have received at least one dose of HPV vaccine within the study period. After the training has been completed, administrators will be asked to continue running regularly scheduled reports over the course of one year. A tracking log will be sent regularly to the research team.
Study: NCT01148719

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Index group
Description: Diagnostic triage strategy includes; electrocardiography, echocardiography, spirometry and blood testing
Study: NCT02348658

Intervention type: DRUG
Group type: OTHER
Intervention: TAK-536TCH
Description: TAK-536TCH tablets
Study: NCT01869114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV
Study: NCT01002794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised neuromuscular and strength training
Description: Supervised exercise therapy in 12 weeks, both neuromuscular- and strength training. Carried out at Nimi Ullevaal Oslo or Gnist trending- og fysioterapi, Baerum
Study: NCT03204474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide (LCM) tablet
Description: Treatment A: Single dose of Lacosamide (LCM) 200 mg given as 2 tablets of LCM 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide (LCM) tablet
Description: Treatment A: Single dose of Lacosamide (LCM) 200 mg given as 2 tablets of LCM 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide (LCM) solution for infusion
Description: Treatment B: Single dose of Lacosamide (LCM) 200 mg administered as intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide (LCM) solution for infusion
Description: Treatment B: Single dose of Lacosamide (LCM) 200 mg administered as intravenous infusion
Study: NCT02640365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-398
Description: unresectable Advanced non-colorectal cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: unresectable metastatic colorectal cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin (LV)
Description: unresectable metastatic colorectal cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracile (5-FU)
Description: unresectable metastatic colorectal cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: unresectable metastatic colorectal cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-398
Description: unresectable metastatic colorectal cancer
Study: NCT01522950

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: 5 mg daily or 10 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atenolol
Description: 25 mg daily or 50 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet daily
Study: NCT01472172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryobiopsy (Autoclavable cryoprobe 20416-032)
Description: The tip of the cryoprobe will be attached to suspicious part of parietal pleura and activated by footswitch for 3 seconds. The frozen tissue is going to be extracted by gently pulling of the probe. The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar. The biopsy sample will be released from the probe by thawing in the saline.
Study: NCT02316756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06648671
Description: Experimental Pfizer compound which will be dosed as oral suspension
Study: NCT03418792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parotid-Sparing Head & Neck Radiation Guided by MRI Sialography
Description: Head \& neck radiation with parotid sparing. Parotid sparing will be facilitated by avoidance of salivary ductal structures and stem cells, as identified by the pre-treatment MRI sialogram, in the radiation treatment plan.
Study: NCT02419235

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 20% ethanol
Description: Unmedicated 20% ethanol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Homoeopathic complex
Description: 20% ethanol medicated with Amylenum nitrosum 6cH, Crataegus oxyacantha 6cH, Natrium muriaticum 6cH and Scutellaria lateriflora 6cH.
Study: NCT04577885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2554 and Rifampin
Description: Single-dose oral administration of SHR2554 and multiple-dose oral administration of Rifampin Capsules
Study: NCT01233713

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hartmann's operation
Description: Hartmann's operation is the surgical resection of the rectosigmoid colon with closure of the rectal stump and end colostomy, followed by a stoma reversal operation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary anastomosis
Description: Primary anastomosis refers to a colonic resection with primary anastomosis and covering proximal ileostomy, followed by a stoma reversal operation.
Study: NCT02316756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06648671
Description: Experimental Pfizer compound which will be dosed as oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06648671
Description: Experimental Pfizer compound which will be dosed as oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo which will be given as oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo which will be given as oral suspension
Study: NCT00873899

Intervention type: DEVICE
Intervention: The Medtronic CareLink system (Minneapolis, MN, USA).
Description: The Medtronic CareLink system(Minneapolis, MN, USA)includes a patient monitor plugged into a standard analog telephone connection, and a lightweight wand to communicate with the implanted device. Interrogation of the device and transmission of the data occur when the patient places the wand over the implanted device. The system uses radio frequency telemetry for wireless automatic communication. This allows for data transmission without patient intervention and enables automatic transmissions at pre-specified routine intervals as well as alert-based downloads.The system can transmit data in case of programmable conditions on diagnostic variables, arrhythmias, delivered ICD therapies, battery/lead issues, and alert the physician via phone or e-mail. The patient's information is sent to a secure Network server via the telephone connection and clinical staff can review device information.Available data are equivalent to that which can be retrieved at an in-office visit.

Intervention type: DEVICE
Intervention: The Medtronic CareLink system (Minneapolis, MN, USA).
Description: The Medtronic CareLink system(Minneapolis, MN, USA)includes a patient monitor plugged into a standard analog telephone connection, and a lightweight wand to communicate with the implanted device. Interrogation of the device and transmission of the data occur when the patient places the wand over the implanted device. The system uses radio frequency telemetry for wireless automatic communication. This allows for data transmission without patient intervention and enables automatic transmissions at pre-specified routine intervals as well as alert-based downloads.The system can transmit data in case of programmable conditions on diagnostic variables, arrhythmias, delivered ICD therapies, battery/lead issues, and alert the physician via phone or e-mail. The patient's information is sent to a secure Network server via the telephone connection and clinical staff can review device information.Available data are equivalent to that which can be retrieved at an in-office visit.
Study: NCT03557788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin Oral Tablet
Description: PO 550mg TDS for 2 weeks
Study: NCT03838835

Intervention type: OTHER
Group type: OTHER
Intervention: WLC
Description: WLC consists of youth who are not yet receiving any services at Gallop NYC.
Study: NCT01332916

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cognitive tests and cerebral IRM
Description: cognitive tests and cerebral IRM

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cognitive tests and cerebral IRM
Description: cognitive tests and cerebral IRM
Study: NCT01170663

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab (IMC-1211B) DP
Description: 8 milligrams/kilogram (mg/kg) intravenous (IV) infusion on Days 1 and 15 of every 4-week cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ramucirumab placebo IV infusion on Days 1 and 15 of every 4-week cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80 milligrams per square meter (mg/m²) IV infusion on Days 1, 8, and 15 of every 4-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 milligrams per square meter (mg/m²) IV infusion on Days 1, 8, and 15 of every 4-week cycle
Study: NCT03896633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brinzolamide 1% ophthalmic suspension
Description: brinzolamide 1% ophthalmic suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azopt 1%
Description: Azopt 1%, RLD
Study: NCT03715790

Intervention type: BEHAVIORAL
Intervention: EP referred group
Description: Referred for sudden cardiac death (SCD) risk stratification and management

Intervention type: BEHAVIORAL
Intervention: Non-Referred group
Description: Not referred for sudden cardiac death (SCD) risk stratification and management.
Study: NCT04435158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1222
Description: Pharmaceutical form: water injection Route of administration: subcutaneous injection
Study: NCT02900326

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance exercise training
Description: In each group, there will be a comparison of aerobic capacity, quality of life (with questionnaires), functional cerebral measurements (fRMI), and telomerase activity between before and after the 8 weeks program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-based-stress-reduction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Both interventions together

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vo2max measurements

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vo2max measurements
Study: NCT04435158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1222
Description: Pharmaceutical form: water injection Route of administration: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1222
Description: Pharmaceutical form: water injection Route of administration: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1222
Description: Pharmaceutical form: water injection Route of administration: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1222
Description: Pharmaceutical form: water injection Route of administration: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: water injection Route of administration: subcutaneous injection
Study: NCT02735200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Application of topical vitamin d3 (Top-D)
Description: Topical Vitamin D3 will be applied on the skin, externally, 1 gram daily for 120 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Application of Aloe vera gel
Description: aloe vera gel will be applied~Dosage: 1 gram Duration: 120 days Frequency: Daily
Study: NCT01621100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS hydromorphone
Description: Type= exact number, unit= mg, number= 4, form= tablet, route= oral, administered from 1st evaluation day (Day 1) to 2nd evaluation day (Day 15±2). Dosage adjustment: If NRS (Numeric Rating Scale) =4 or more then dose can be increased by 4mg until the average pain intensity for the past 24 hours is adjusted to lower than NRS 3. For the treatment of breakthrough pain, if necessary the one-time administration dose of quick-effect OROS Hydromorphone shall be 2mg up to the daily dosage of the study medicine, 12mg.
Study: NCT02279927

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ureteroscopy
Description: Ureteroscopy with laser stone fragmentation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ureteroscopy
Description: Ureteroscopy with laser stone fragmentation
Study: NCT03326908

Intervention type: DEVICE
Group type: OTHER
Intervention: Spectral Domain Optical Coherence Tomography
Description: Five SD-OCTs will be performed with various conditions of enlightenment.

Intervention type: DEVICE
Group type: OTHER
Intervention: Spectral Domain Optical Coherence Tomography
Description: Five SD-OCTs will be performed with various conditions of enlightenment.
Study: NCT02519842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for fosaprepitant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron